Idiopathic inflammatory myopathies

Melinda Vincze, K. Dankó

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Inflammatory myopathies are chronic, immune-mediated diseases characterised by progressive proximal muscle weakness. They encompass a variety of syndromes with protean manifestations. The diagnosis is based on Bohan and Peter's classification criteria, which nowadays seem to be obsolete. Our increasing knowledge about the risk factors, genetic susceptibility and immunological pathways in the disease mechanism leads to the establishment of a new, immunogenetically and serologically validated diagnostic criteria system. The treatment of idiopathic inflammatory myopathy is also a complex task requiring much experience. The aims of therapy are to increase muscle strength, prevent the development of contractures and manage the systemic manifestations of the disease. The most important one is the early detection of diseases and patients' immunological control in special centres. Using the basis therapeutic drugs temporary or permanent remission can be achieved, which improves patientsG' quality of life and functional ability. Rehabilitation and physiotherapy in the remission period may significantly improve the outcome of patients with functional disorders. The introduction of new biological therapies further allows us to control the myositis patients' state more effectively. The aim of this review is to summarise our knowledge about clinical symptoms, pathomechanism, as well as genetic, serologic and environmental risk factors. We would also like to present the way to diagnosis and the latest research about diagnostic criteria system, proposed outcome measures and therapeutic possibilities.

Original languageEnglish
Pages (from-to)25-45
Number of pages21
JournalBest Practice and Research: Clinical Rheumatology
Volume26
Issue number1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Myositis
Biological Therapy
Delayed Diagnosis
Immune System Diseases
Muscle Weakness
Muscle Strength
Contracture
Therapeutics
Genetic Predisposition to Disease
Early Diagnosis
Rehabilitation
Quality of Life
Outcome Assessment (Health Care)
Research
Pharmaceutical Preparations

Keywords

  • Cancer-associated myositis
  • Dermatomyositis
  • Inclusion body myositis
  • Necrotising myopathy
  • Polymyositis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Idiopathic inflammatory myopathies. / Vincze, Melinda; Dankó, K.

In: Best Practice and Research: Clinical Rheumatology, Vol. 26, No. 1, 02.2012, p. 25-45.

Research output: Contribution to journalArticle

@article{bdbacaab1e3747b29fcfe9b84dd8d536,
title = "Idiopathic inflammatory myopathies",
abstract = "Inflammatory myopathies are chronic, immune-mediated diseases characterised by progressive proximal muscle weakness. They encompass a variety of syndromes with protean manifestations. The diagnosis is based on Bohan and Peter's classification criteria, which nowadays seem to be obsolete. Our increasing knowledge about the risk factors, genetic susceptibility and immunological pathways in the disease mechanism leads to the establishment of a new, immunogenetically and serologically validated diagnostic criteria system. The treatment of idiopathic inflammatory myopathy is also a complex task requiring much experience. The aims of therapy are to increase muscle strength, prevent the development of contractures and manage the systemic manifestations of the disease. The most important one is the early detection of diseases and patients' immunological control in special centres. Using the basis therapeutic drugs temporary or permanent remission can be achieved, which improves patientsG' quality of life and functional ability. Rehabilitation and physiotherapy in the remission period may significantly improve the outcome of patients with functional disorders. The introduction of new biological therapies further allows us to control the myositis patients' state more effectively. The aim of this review is to summarise our knowledge about clinical symptoms, pathomechanism, as well as genetic, serologic and environmental risk factors. We would also like to present the way to diagnosis and the latest research about diagnostic criteria system, proposed outcome measures and therapeutic possibilities.",
keywords = "Cancer-associated myositis, Dermatomyositis, Inclusion body myositis, Necrotising myopathy, Polymyositis",
author = "Melinda Vincze and K. Dank{\'o}",
year = "2012",
month = "2",
doi = "10.1016/j.berh.2012.01.013",
language = "English",
volume = "26",
pages = "25--45",
journal = "Best Practice and Research in Clinical Rheumatology",
issn = "1521-6942",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

TY - JOUR

T1 - Idiopathic inflammatory myopathies

AU - Vincze, Melinda

AU - Dankó, K.

PY - 2012/2

Y1 - 2012/2

N2 - Inflammatory myopathies are chronic, immune-mediated diseases characterised by progressive proximal muscle weakness. They encompass a variety of syndromes with protean manifestations. The diagnosis is based on Bohan and Peter's classification criteria, which nowadays seem to be obsolete. Our increasing knowledge about the risk factors, genetic susceptibility and immunological pathways in the disease mechanism leads to the establishment of a new, immunogenetically and serologically validated diagnostic criteria system. The treatment of idiopathic inflammatory myopathy is also a complex task requiring much experience. The aims of therapy are to increase muscle strength, prevent the development of contractures and manage the systemic manifestations of the disease. The most important one is the early detection of diseases and patients' immunological control in special centres. Using the basis therapeutic drugs temporary or permanent remission can be achieved, which improves patientsG' quality of life and functional ability. Rehabilitation and physiotherapy in the remission period may significantly improve the outcome of patients with functional disorders. The introduction of new biological therapies further allows us to control the myositis patients' state more effectively. The aim of this review is to summarise our knowledge about clinical symptoms, pathomechanism, as well as genetic, serologic and environmental risk factors. We would also like to present the way to diagnosis and the latest research about diagnostic criteria system, proposed outcome measures and therapeutic possibilities.

AB - Inflammatory myopathies are chronic, immune-mediated diseases characterised by progressive proximal muscle weakness. They encompass a variety of syndromes with protean manifestations. The diagnosis is based on Bohan and Peter's classification criteria, which nowadays seem to be obsolete. Our increasing knowledge about the risk factors, genetic susceptibility and immunological pathways in the disease mechanism leads to the establishment of a new, immunogenetically and serologically validated diagnostic criteria system. The treatment of idiopathic inflammatory myopathy is also a complex task requiring much experience. The aims of therapy are to increase muscle strength, prevent the development of contractures and manage the systemic manifestations of the disease. The most important one is the early detection of diseases and patients' immunological control in special centres. Using the basis therapeutic drugs temporary or permanent remission can be achieved, which improves patientsG' quality of life and functional ability. Rehabilitation and physiotherapy in the remission period may significantly improve the outcome of patients with functional disorders. The introduction of new biological therapies further allows us to control the myositis patients' state more effectively. The aim of this review is to summarise our knowledge about clinical symptoms, pathomechanism, as well as genetic, serologic and environmental risk factors. We would also like to present the way to diagnosis and the latest research about diagnostic criteria system, proposed outcome measures and therapeutic possibilities.

KW - Cancer-associated myositis

KW - Dermatomyositis

KW - Inclusion body myositis

KW - Necrotising myopathy

KW - Polymyositis

UR - http://www.scopus.com/inward/record.url?scp=84858376034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858376034&partnerID=8YFLogxK

U2 - 10.1016/j.berh.2012.01.013

DO - 10.1016/j.berh.2012.01.013

M3 - Article

VL - 26

SP - 25

EP - 45

JO - Best Practice and Research in Clinical Rheumatology

JF - Best Practice and Research in Clinical Rheumatology

SN - 1521-6942

IS - 1

ER -